FSHD Study Links DNA Methylation to Milder Muscle Disease
A study of a nine-generation family found that higher DNA methylation at the DUX4 gene was associated with milder facioscapulohumeral muscular dystrophy. The finding points to a possible genetic dimmer switch that could help predict disease severity and guide treatment research.

Researchers studying a nine-generation Utah family found that higher DNA methylation at the DUX4 gene was associated with milder facioscapulohumeral muscular dystrophy (FSHD), a finding that points to a genetic dimmer switch that may protect against severe symptoms.
The disease weakens muscles in the face, shoulders and limbs. People with the same disease-causing genetic change can have very different outcomes.
Two siblings in the family shared that change. The brother began noticing weakness in his early teens and could barely walk by his 50s. His sister remained symptom-free into her late 30s and was only mildly affected throughout her life.
Researchers compared clinical records with sequencing of stored DNA samples. They found that people with higher methylation at DUX4 tended to have milder symptoms.
DNA methylation can reduce a gene’s activity or turn it off. In people with FSHD, DUX4 becomes active in adulthood and triggers processes that damage muscles.
“Methylation had been suspected, but nobody had clearly unraveled it,” said Robert Weiss, professor of human genetics at University of Utah Health and the study’s senior author. “This helps clarify a long-standing question in the field.”
The family has worked with University of Utah geneticists since the 1940s, and its stored DNA samples date back to the 1980s. Researchers used a targeted long-read sequencing tool to analyze DUX4, a region with long, repetitive DNA sequences that are difficult to study.
The team also linked higher DUX4 methylation to a specific DNA change near HDGFL3, a little-studied gene that may help regulate methylation. Researchers said the gene’s role is not well understood and needs further study.
The findings could help researchers predict how FSHD progresses and identify treatment targets. Potential approaches include increasing HDGFL3 activity or directly increasing methylation at DUX4.
A clinical trial designed to increase DUX4 methylation is underway, said Russell Butterfield, the study’s lead author and a professor of pediatrics and neurology at University of Utah Health. “We just treated our first gene therapy patient a few weeks ago,” he said.
The results were published in Brain. “We’re hopeful that this work will lead to better outcomes for people living with these rare diseases,” Weiss said.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage

- 2Women With Autoimmune Diseases Wait About 4 Years for Diagnosis, Study Finds

- 3DUP Chairman Lord Morrow Loses Wife and Daughter Within Hours in NI

- 4Micron Stock Falls 28% as $35.16 Billion Buyback Nears

- 5I’m A Celebrity 2026 Line-Up: Rooney Leads 11 Stars Into Jungle

Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists
LifestylePeople Who Don’t Like Celebrating Their Birthday Often Share These 7 Traits















